Pricing Log in Create free account
Friday 6 November 2026 Export ARGX’s income statement to Excel — free account

argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.

Revenue
+52.1%
EPS
+43.9%
Free cash flow
+537.5%

Quarter to September 2026, against a year earlier

922.55 27.78 +3.10%
Market cap
$56.3B
P/E
29.8×
Fwd P/E
30.1×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

argenex SE (ARGX) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, argenex SE (ARGX) trades at a EV/EBITDA of 30.4×. Over the past ten years it has ranged from 0.0× (March 2025) to 183× (May 2025); the current reading is higher than 84% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 45.6× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 32.5× (3.95%)
Jun 2026 33.9× 5.93%
Mar 2026 32.0× (29.92%)
Dec 2025 45.6× (16.57%)
25 more quarters

Against its own ten years

Low 0.0× High 183×
Ten-year median 0.0×
Current reading's percentile 84

EV/EBITDA against peers

Company EV/EBITDA
ROIV Roivant Sciences Ltd. compare n/m
MRNA Moderna, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. compare 16.0×
RPRX Royalty Pharma PLC compare 24.7×
INCY Incyte Corporation compare 27.9×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 28.6×
ARGX argenex SE 30.4×
GMAB Genmab A/S Sponsored ADR compare 31.0×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ARGX